Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Keegan Begley as the company’s President.
“Kolosis is very excited to welcome Keegan as the newest member of our executive team,” said Collin Begley, Chief Executive Officer at Kolosis. “As the company’s new President, and a member of our Board of Directors, Keegan will provide both vital strategic contributions as well as daily leadership for our extensive sales partner network. Keegan is universally regarded as one of the industry’s most talented sales leaders and we are ecstatic to have him in this key position.”
Prior to joining Kolosis, Keegan served as Executive Vice President, Sales at Centurion Therapeutics where he managed an inside and independent sales network supporting MTF Wound Care tissues. Prior to that, Keegan was an award winning sales manager at Orthofix where he represented MTF bone graft tissues.
“I could not be more excited to join the team at Kolosis BIO,” said Keegan Begley. “I believe we are going to build a tremendous success story here at Kolosis. By combining best in class bone graft technologies with a culture built upon relentless responsiveness and execution, we will meet the needs of our distribution partners, their surgeons, and most importantly the patients we serve.”
Kolosis BIO is a pure-play orthobiologics company dedicated to commercializing Bold Technologies with Relentless Execution. Kolosis exclusively partners with MTF to deliver market-leading bone graft technologies in the orthopedic space. The company represents two MTF bone graft technologies; Kore Fiber, a 100% cortical fiber allograft, and Prime HD, a pre-hydrated DBM. Both grafts offer superior quality through MTF’s proprietary aseptic processing methods which optimally preserve matrix structures and osteoinductive properties. For more information visit www.kolosis.com.